August 12th 2020
Nilanjan Ghosh, MD, PhD, discusses the role of minimal residual disease in chronic lymphocytic leukemia.
August 10th 2020
Paolo Ghia, MD, PhD, discusses overall survival data with acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND trial.
August 6th 2020
The FDA has cleared the clonoSEQ® assay to identify and monitor minimal residual disease in blood or bone marrow from patients with chronic lymphocytic leukemia.
August 4th 2020
Othman Al-Sawaf, MD, discusses new safety signals with venetoclax plus obinutuzumab in the phase 3 CLL14 trial.
July 30th 2020
July 24th 2020
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for ibrutinib in combination with rituximab for use in treatment-naïve patients with chronic lymphocytic leukemia.
July 20th 2020
Othman Al-Sawaf, MD, discusses ongoing minimal residual disease assessment for patients in the phase 3 CLL14 study with chronic lymphocytic leukemia.
July 17th 2020
Matthew S. Davids, MD, MMSc, discusses the design of the UNITY trials in patients with relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.
Ian W. Flinn, MD, PhD, discusses the adverse effects associated with BTK inhibitors in B-cell malignancies, as well as the design of an ongoing phase 2 study with zanubrutinib.
Othman Al-Sawaf, MD, discusses the data from the CLL14 trial with obinutuzumab/venetoclax and the benefits of a fixed-dose treatment in select patients with chronic lymphocytic leukemia.
